Search clinical trials for: ISIS apoC-III Rx

Total 56 results

Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

Hypertriglyceridemia

United States, Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

Elevated Lipoprotein(a)

Netherlands, United Kingdom, Denmark, Germany, Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

Elevated Triglycerides (TG)

Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome

United States, Brazil, Canada, France, Germany, Hungary, Israel, Italy, Netherlands, South Africa, Spain, United Kingdom
Ionis Pharmaceuticals, Inc.
Bayer

Completed

A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis

End-stage Renal Disease (ESRD)

Canada
Biogen

Completed

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies (SHINE)

Spinal Muscular Atrophy

United States, Spain, Germany, United Kingdom, Australia, Japan, Canada, Belgium, France, Hong Kong, Italy, Korea, Republic of, Sweden, Turkey
Biogen

Completed

An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) (SMNRx)

Spinal Muscular Atrophy

United States
Biogen

Completed

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy

United States, Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis

Rheumatoid Arthritis

Canada, Russian Federation
Biogen

Completed

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

Spinal Muscular Atrophy

United States
Biogen

Terminated

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (ENDEAR)

Spinal Muscular Atrophy

Korea, Republic of, United States, Spain, Canada, Germany, Australia, Japan, Sweden, Belgium, France, Italy, Turkey, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Amyloidosis | Familial Amyloid Polyneuropathy | FAP | TTR | Transthyretin

United States, Spain, Argentina, Brazil, France, Germany, Italy, Portugal, United Kingdom
Biogen

Completed

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)

Spinal Muscular Atrophy

United States
Ionis Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Amyloidosis | Familial Amyloid Polyneuropathy | FAP | TTR | Transthyretin

New Zealand, United States, Spain, Argentina, Brazil, France, Germany, Italy, Portugal, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation (ASET)

Paroxysmal Atrial Fibrillation

United Kingdom
Biogen

Completed

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) (CHERISH)

Spinal Muscular Atrophy

United States, Germany, Spain, Canada, France, Hong Kong, Italy, Japan, Korea, Republic of, Sweden
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants

Healthy Participants

United States
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

Cardiovascular Disease | Elevated Lipoprotein(a)

United States, Canada, Denmark, Germany, Netherlands
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (NSCLC)

Non-small Cell Lung Cancer

United States, Hungary, Poland, Russian Federation
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Castrate-Resistant Prostate Cancer

United States, Puerto Rico, Hungary, Romania, Russian Federation, Poland
University of Minnesota
3M

Completed

Evaluation of a "Flash-free" Adhesive Resin for Orthodontic Bracket Bonding

Malocclusion

United States
Hospital San Carlos, Madrid

Recruiting

CRyoAblation vs AntiaRrhythmic Drugs for Persistent Atrial Fibrillation Trial (craft)

Atrial Fibrillation

Spain
Medtronic Cardiovascular

Recruiting

Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial (ADVANCE)

Abdominal Aortic Aneurysm | Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder) | Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)

Japan, United States, Taiwan, France, Germany, Switzerland, Italy, Netherlands, Finland, Spain, United Kingdom
University Hospital, Bordeaux

Unknown

Ultrasound Monitoring of Fetuses With Vascular Intra-uterine Growth Restriction (IUGR) Using the Isthmus Systolic Index (ISI): Feasibility, Comparison to Normal Fetuses and Association With Perinatal Mortality (f-ISI-RCIU)

IUGR

France
Rijnstate Hospital
Medtronic

Recruiting

Comparison of EVAR and ESAR for Infrarenal Aortic Aneurysms With a Wide Proximal Neck (HERCULES)

Aortic Aneurysm, Abdominal

Netherlands, United States
Biotronik France
Biotronik SE & Co. KG

Completed

Observational Study of Patient Comprehension, Perception, Fears and Appreciation Following Home-Monitoring Implementation (Educ@t)

Tachycardia | Defibrillators

France
Instituto de Investigacion Sanitaria La Fe

Recruiting

Comparison of Efficacy and Side Effects Between the Obtryx and Solyx Band With 5-year Follow-up.

Stress Urinary Incontinence

Spain
Centre Hospitalier Universitaire de Saint Etienne

Completed

Assessment of the Quality of Sleep and Sleep Disorders Among the Professional and Volunteer Firefighters of Loire (FIRESLEEP)

Firefighter

France
Melinta Therapeutics, Inc.

Completed

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia (DEFINE-CABP)

Community Acquired Bacterial Pneumonia

United States, Argentina, Bulgaria, Colombia, Dominican Republic, Georgia, Germany, Hungary, Latvia, Peru, Poland, Romania, Russian Federation, Serbia, Slovenia, South Africa, Spain, Ukraine
Sheba Medical Center

Completed

Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII

Hemophilia A
Case Comprehensive Cancer Center

Completed

A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer

Breast Cancer | Sleep

United States
Guy's and St Thomas' NHS Foundation Trust

Completed

Bond Failure of Two Types of Molar Buccal Tubes

Orthodontic Appliance Complication

United Kingdom
Tehran University of Medical Sciences

Unknown

Methylphenidate on Intracortical Inhibition in Methamphetamine Abusers Attention Deficit Hyperactivity Disorder (ADHD) (ADHD)

Attention Deficit Hyperactivity Disorder

Iran, Islamic Republic of
Ohio State University Comprehensive Cancer Center

Completed

Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors

Tongue Cancer | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage I Verrucous Carcinoma of the Oral Cavity | Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage... and other conditions

United States
University Hospital, Geneva
University of Geneva, Switzerland

Not yet recruiting

Mental Imagery and Targeted Memory Reactivation in Insomnia

Insomnia Disorder

Switzerland
Ottawa Hospital Research Institute
University of Manitoba; St. Joseph's Healthcare Hamilton; University Health Network... and other collaborators

Completed

Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study

Kidney Transplant Infection | Disease Due to BK Polyomavirus

Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

Healthy

United States
Sir Mortimer B. Davis - Jewish General Hospital
Merck Frosst Canada Ltd.

Terminated

Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects

Pre-diabetes | Pre-hypertension

Canada
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

Small Cell Lung Cancer

Poland, Russian Federation, United States, Austria, Canada, Hungary, Israel, Italy, Korea, Republic of, Spain, Switzerland
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)

Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | Pertuzumab

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Adenocarcinoma | NSCLC | Squamous Cell Carcinoma
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast Carcinoma

United States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)

Hormone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Australia, Puerto Rico, New Zealand, Ireland, Peru, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
Northwestern University
National Cancer Institute (NCI); BHR Pharma, LLC

Recruiting

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Estrogen Receptor Positive | Ductal Breast Carcinoma In Situ

United States
National Cancer Institute (NCI)

Completed

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | Progesterone Receptor Positive | Male Breast Carcinoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Stage 0 Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | HER2/Neu Negative | Postmenopausal

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Recurrent Ovarian Low Grade Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Recurrent Primary Peritoneal Serous Adenocarcinoma

United States, United Kingdom
Jennifer Lee Caswell-Jin
National Cancer Institute (NCI); QED Therapeutics, Inc.

Terminated

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer

United States
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland

Search clinical trials for: ISIS apoC-III Rx

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations